Skip to main content
. 2019 Jan;25(1):10.18553/jmcp.2019.25.1.018. doi: 10.18553/jmcp.2019.25.1.018

Table 4.

Number and Costs of Health Care Resources for Each Cohorta

Unadjusted Costsb
Variable Abusers (n = 77,369) Controls (n = 77,369) P Valuec At Risk (n = 150,214) Controls (n = 150,214) P Valuec
Inpatients
  Pre-index visits 0.2 (0.6) 0.1 (0.3) <0.0001 0.1 (0.4) 0.1 (0.3) < 0.0001
  Post-index visits 0.3 (0.8) 0.1 (0.3) <0.0001 0.2 (0.6) 0.1 (0.3) < 0.0001
  Pre-index costs 7,042 (36,035) 2,686 (23,648) <0.0001 5,399 (35,763) 2,769 (21,807) < 0.0001
  Post-index costs 12,653 (56,724) 2,701 (22,759) <0.0001 9,940 (46,119) 3,151 (21,819) < 0.0001
  Annual costs 19,695 (72,146) 5,387 (33,899) <0.0001 15,338 (61,922) 5,920 (32,111) < 0.0001
Outpatients
  Pre-index visits 2.8 (4.9) 1.6 (3.5) < 0.0001 2.4 (4.5) 1.9 (3.8) < 0.0001
  Post-index visits 3.0 (5.2) 1.7 (3.7) < 0.0001 2.9 (5.1) 1.9 (3.8) < 0.0001
  Pre-index costs 6,557 (29,744) 5,387 (32,749) < 0.0001 6,055 (29,122) 5,634 (31,217) < 0.0001
  Post-index costs 6,892 (30,797) 6,365 (37,987) < 0.0001 7,311 (33,033) 6,000 (32,720) < 0.0001
  Annual costs 13,449 (55,962) 11,752 (67,850) < 0.0001 13,366 (57,526) 11,634 (61,491) < 0.0001
Emergency
  Pre-index visits 3.4 (7.7) 0.6 (1.6) < 0.0001 1.1 (2.4) 0.5 (1.4) < 0.0001
  Post-index visits 3.9 (7.9) 0.6 (1.6) < 0.0001 1.7 (3.0) 0.5 (1.4) < 0.0001
  Pre-index costs 2,494 (5,634) 460 (1,372) < 0.0001 805 (1,943) 389 (1,178) < 0.0001
  Post-index costs 3,518 (6,496) 495 (1,410) < 0.0001 1,593 (2,896) 431 (1,269) < 0.0001
  Annual costs 6,011 (11,150) 955 (2,296) < 0.0001 2,398 (4,119) 820 (1,991) < 0.0001
Pharmacy
  Pre-index costs 3,520 (4,984) 1,895 (3,988) < 0.0001 2,520 (3,910) 1,640 (3,107) < 0.0001
  Post-index costs 3,518 (5,289) 1,975 (4,352) < 0.0001 2,601 (3,956) 1,672 (3,322) < 0.0001
  Annual costs 7,038 (9,645) 3,870 (8,086) < 0.0001 5,121 (7,468) 3,312 (6,230) < 0.0001
Total cost
  Pre-index costs 19,614 (50,681) 10,428 (42,599) < 0.0001 14,779 (49,214) 10,432 (40,314) < 0.0001
  Post-index costs 26,580 (68,639) 11,536 (46,794) < 0.0001 21,445 (60,045) 11,253 (41,581) < 0.0001
  Annual costs 46,194 (100,608) 21,964 (80,531) < 0.0001 36,224 (91,735) 21,685 (74,004) < 0.0001
Adjusted Post-Index Costsd
  Inpatient 12,600 (11,220) 2,670 (3,251) < 0.0001 9,861 (7,922) 3,254 (3,357) < 0.0001
  Outpatient 7,580 (26,042) 6,223 (24,559) < 0.0001 7,834 (26,683) 6,335 (25,254) < 0.0001
  Emergency 3,476 (2,167) 509 (397) < 0.0001 1,589 (753.3) 435 (313) < 0.0001
  Pharmacy 3,667 (2,659) 1,914 (1,085) < 0.0001 2,661 (1,529) 1,642 (944) < 0.0001
  Total 33,942 (54,445) 10,754 (17,613) < 0.0001 24,208 (36,164) 11,692 (21,806) < 0.0001

aValues in this table are shown as mean (SD).

bIncludes patients with zero costs.

cKruskal Wallis test P values for overall abuse versus overall control.

dMedical costs were adjusted for differences in patient demographics and comorbidities between abuse/dependence patients and their matched controls by claim type, subtotal, and total, using multivariate regression analyses. Because cost data are not normally distributed, a 2-step model was used. In the first step, a logit regression model predicted a probability for each patient of having costs by claim type, as well as for subtotal and total costs based on patient age, gender, race, region, poisonings, and comorbidities. The second step used a log normal regression analysis to estimate conditional costs for patients with nonzero costs and also adjusted for age, gender, race, region, poisonings, and comorbidities. This adjusted log transformed cost was retransformed then multiplied by the patient’s probability of having a nonzero cost. This step adjusted the estimated mean cost downward to account for zero cost patients.

SD = standard deviation.